<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Glinton K</submitter><funding>NCATS NIH HHS</funding><funding>NIAID NIH HHS</funding><funding>NHLBI NIH HHS</funding><funding>National Institutes of Health</funding><pagination>435-446</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8169599</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>40(6)</volume><pubmed_abstract>Cardiac Allograft Vasculopathy (CAV) is a leading contributor to late transplant rejection. Although implicated, the mechanisms by which bone marrow-derived cells promote CAV remain unclear. Emerging evidence implicates the cell surface receptor tyrosine kinase AXL to be elevated in rejecting human allografts. AXL protein is found on multiple cell types, including bone marrow-derived myeloid cells. The causal role of AXL from this compartment and during transplant is largely unknown. This is important because AXL is a key regulator of myeloid inflammation. Utilizing experimental chimeras deficient in the bone marrow-derived Axl gene, we report that Axl antagonizes cardiac allograft survival and promotes CAV. Flow cytometric and histologic analyses of Axl-deficient transplant recipients rev</pubmed_abstract><journal>The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</journal><pubmed_title>Bone marrow-derived AXL tyrosine kinase promotes mitogenic crosstalk and cardiac allograft vasculopathy.</pubmed_title><pmcid>PMC8169599</pmcid><funding_grant_id>UL1 TR001422</funding_grant_id><funding_grant_id>R01 HL122309</funding_grant_id><funding_grant_id>R01 HL139812</funding_grant_id><funding_grant_id>R01 AI114824</funding_grant_id><pubmed_authors>Ansari MJ</pubmed_authors><pubmed_authors>Lomasney J</pubmed_authors><pubmed_authors>Sinha A</pubmed_authors><pubmed_authors>Leventhal JR</pubmed_authors><pubmed_authors>Feinstein M</pubmed_authors><pubmed_authors>Glinton K</pubmed_authors><pubmed_authors>Thorp EB</pubmed_authors><pubmed_authors>Fisher E</pubmed_authors><pubmed_authors>Wasserstrom JA</pubmed_authors><pubmed_authors>Zhang ZJ</pubmed_authors><pubmed_authors>DeBerge M</pubmed_authors><pubmed_authors>Schroth S</pubmed_authors><pubmed_authors>Forbess JM</pubmed_authors><pubmed_authors>Luo X</pubmed_authors><pubmed_authors>Wang JJ</pubmed_authors></additional><is_claimable>false</is_claimable><name>Bone marrow-derived AXL tyrosine kinase promotes mitogenic crosstalk and cardiac allograft vasculopathy.</name><description>Cardiac Allograft Vasculopathy (CAV) is a leading contributor to late transplant rejection. Although implicated, the mechanisms by which bone marrow-derived cells promote CAV remain unclear. Emerging evidence implicates the cell surface receptor tyrosine kinase AXL to be elevated in rejecting human allografts. AXL protein is found on multiple cell types, including bone marrow-derived myeloid cells. The causal role of AXL from this compartment and during transplant is largely unknown. This is important because AXL is a key regulator of myeloid inflammation. Utilizing experimental chimeras deficient in the bone marrow-derived Axl gene, we report that Axl antagonizes cardiac allograft survival and promotes CAV. Flow cytometric and histologic analyses of Axl-deficient transplant recipients rev</description><dates><release>2021-01-01T00:00:00Z</release><publication>2021 Jun</publication><modification>2025-04-22T21:54:55.234Z</modification><creation>2025-04-06T03:52:10.181Z</creation></dates><accession>S-EPMC8169599</accession><cross_references><pubmed>33846079</pubmed><doi>10.1016/j.healun.2021.03.006</doi></cross_references></HashMap>